{"id":6153,"date":"2025-09-10T09:29:21","date_gmt":"2025-09-10T07:29:21","guid":{"rendered":"https:\/\/www.ehc.eu\/non-classifiee\/lehc-exhorte-lue-a-ajouter-le-facteur-von-willebrand-a-la-liste-des-medicaments-critiques\/"},"modified":"2026-04-02T16:31:50","modified_gmt":"2026-04-02T14:31:50","slug":"lehc-exhorte-lue-a-ajouter-le-facteur-von-willebrand-a-la-liste-des-medicaments-critiques","status":"publish","type":"post","link":"https:\/\/www.ehc.eu\/fr\/nouvelles\/lehc-exhorte-lue-a-ajouter-le-facteur-von-willebrand-a-la-liste-des-medicaments-critiques\/","title":{"rendered":"L\u2019EHC exhorte l\u2019UE \u00e0 ajouter le facteur von Willebrand \u00e0 la liste des m\u00e9dicaments critiques"},"content":{"rendered":"<!-- hero -->\t<section   class=\"subpage-hero bg-white\">\n\t\t<div class=\"container\">\n\t\t\t<div class=\"relative z-10\">\n\t\t\t\t<div class=\"pt-16 lg:pt-24 pb-24 lg:pb-32\">\n\t\t\t\t\t<div class=\"row justify-between gap-10 lg:gap-0 mt-10 text-center lg:text-left\">\n\t\t\t\t\t\t<div class=\"w-full lg:w-6\/12 lg:self-center\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"title h2\" data-scroll data-fade-up>\n\t\t\t\t\t\t\t\t\t<p class=\"text-[115%]\">L\u2019EHC exhorte l\u2019UE \u00e0 ajouter le facteur von Willebrand \u00e0 la liste des m\u00e9dicaments critiques<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<figure class=\"absolute size-[41.8rem] lg:size-[82.8rem] bottom-[-10%] right-[-10rem] lg:right-[-5%] image-contain opacity-100 skip-lazy\" data-parallax>\n\t\t\t\t\t<img decoding=\"async\" loading=\"eager\" src=\"https:\/\/etngbd86n6b.exactdn.com\/wp-content\/themes\/cbd\/img\/content-logo-colorfull-2.svg\" alt=\"content-logo-colorfull\">\n\t\t\t\t<\/figure>\n\t\t\t\t\t\t<\/section>\n<!-- overview -->\t<section   class=\"s-overlay-img s-padding bg-red\">\n\t\t<div class=\"container\">\n\t\t\t<div class=\"row w-full lg:flex-row justify-between text-center lg:text-left gap-14 lg:gap-0 relative z-10\">\n\t\t\t\t\t\t\t\t<div class=\"w-full lg:py-10\">\n\t\t\t\t\t<div class=\"bg-white min-h-full py-12 px-10 lg:py-24 lg:pl-24 xl:pl-44 relative radius-20 z-10\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"content mt-8\" data-scroll data-fade-up>\n\t\t\t\t\t\t\t\t<p><!-- wp:paragraph --><\/p>\n<p>L\u2019EHC demande \u00e0 <a href=\"https:\/\/www.ema.europa.eu\/en\/homepage\" target=\"_blank\" rel=\"noopener\"><strong>l\u2019Agence europ\u00e9enne des m\u00e9dicaments (EMA)<\/strong><\/a> d\u2019inclure <strong>le facteur von Willebrand (VWF) dans la liste de l\u2019Union des m\u00e9dicaments critiques, soulignant<\/strong> l\u2019urgence de prot\u00e9ger <strong>les patients atteints <a href=\"https:\/\/community.ehc.eu\/focus-area\/von-willebrand-disease-vwd\/\" target=\"_blank\" rel=\"noopener\">de la maladie de von Willebrand (VWD).<\/a><\/strong><\/p>\n<p><!-- \/wp:paragraph --> <!-- wp:paragraph --><\/p>\n<p>La VWD touche entre 0,6 % et 1,3 % de la population, ce qui en fait le trouble h\u00e9morragique h\u00e9r\u00e9ditaire le plus courant. Pour les patients atteints de VWD de type 3 et beaucoup atteints de VWD de type 2, la VWF repr\u00e9sente une th\u00e9rapie salvatrice lorsque des traitements alternatifs comme la desmopressine s\u2019av\u00e8rent inefficaces. <\/p>\n<p><!-- \/wp:paragraph --> <!-- wp:paragraph --><\/p>\n<p>Sans acc\u00e8s fiable \u00e0 la VWF, les patients font face \u00e0 des \u00e9pisodes de saignement potentiellement mortels, \u00e0 une augmentation des hospitalisations et \u00e0 des cons\u00e9quences potentiellement fatales. Les p\u00e9nuries actuelles mettent non seulement en danger la vie des patients, mais font aussi grimper les co\u00fbts de sant\u00e9 gr\u00e2ce aux interventions d\u2019urgence et aux hospitalisations prolong\u00e9es. <\/p>\n<p><!-- \/wp:paragraph --> <!-- wp:paragraph --><\/p>\n<p>Bien que la desmopressine reste une option pour certains patients atteints de VWD de type 1, elle ne peut pas constituer une solution globale couvrant l\u2019ensemble des cas de VWD. Inclure le VWF dans la liste des m\u00e9dicaments essentiels d\u00e9montrerait l\u2019engagement de l\u2019UE en faveur d\u2019une prise en charge \u00e9quitable des maladies rares et renforcerait la pr\u00e9paration de l\u2019Europe face aux p\u00e9nuries de m\u00e9dicaments. <\/p>\n<p><!-- \/wp:paragraph --> <!-- wp:paragraph --><\/p>\n<p>Ajouter le VWF \u00e0 cette liste repr\u00e9sente une \u00e9tape cruciale pour garantir qu\u2019aucun patient ne souffre inutilement \u00e0 cause de p\u00e9nuries de m\u00e9dicaments \u00e9vitables.<\/p>\n<p><!-- \/wp:paragraph --><\/p>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"bottom mt-12\" data-scroll data-fade-up>\n\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.ehc.eu\/wp-content\/uploads\/2025\/09\/EHC-statement-on-VWF-inclusion.pdf\" target=\"_blank\" class=\"btn with-icon\">\n\t\t\t\t\t\t\t\t\t<span>Read the full EHC statement <\/span>\n\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/section>\n\n<p><\/p>\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>L\u2019EHC demande \u00e0 l\u2019Agence europ\u00e9enne des m\u00e9dicaments d\u2019inclure le facteur von Willebrand dans la liste de l\u2019Union des m\u00e9dicaments critiques, soulignant l\u2019urgence de prot\u00e9ger les patients atteints de la maladie de von Willebrand.<\/p>\n","protected":false},"author":4,"featured_media":4832,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[64,108],"tags":[135,127,207,208],"class_list":["post-6153","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-nouvelles","category-sensibilisation","tag-campagne","tag-document-de-position","tag-liste-des-medicaments-critiques-de-lue","tag-vwd"],"acf":[],"jetpack_featured_media_url":"https:\/\/etngbd86n6b.exactdn.com\/wp-content\/uploads\/2025\/09\/EHC-statement-on-VWF-2025-Blog-Banner.jpg?strip=all&sharp=1","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/posts\/6153","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/comments?post=6153"}],"version-history":[{"count":1,"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/posts\/6153\/revisions"}],"predecessor-version":[{"id":6157,"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/posts\/6153\/revisions\/6157"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/media\/4832"}],"wp:attachment":[{"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/media?parent=6153"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/categories?post=6153"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ehc.eu\/fr\/wp-json\/wp\/v2\/tags?post=6153"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}